WO2011082267A8 - Composés triazolo-pyrazine substitués - Google Patents
Composés triazolo-pyrazine substitués Download PDFInfo
- Publication number
- WO2011082267A8 WO2011082267A8 PCT/US2010/062429 US2010062429W WO2011082267A8 WO 2011082267 A8 WO2011082267 A8 WO 2011082267A8 US 2010062429 W US2010062429 W US 2010062429W WO 2011082267 A8 WO2011082267 A8 WO 2011082267A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- pyrazine compounds
- substituted triazolo
- triazolo
- pyrazine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
Abstract
L'invention concerne des composés triazolo-pyrazine substitués et des procédés pour synthétiser ces composés. Cette invention concerne également des compositions pharmaceutiques contenant des composés triazolo-pyrazine substitués, ainsi que des méthodes pour traiter des troubles de la prolifération cellulaire, tels que le cancer, par administration de ces composés et compositions pharmaceutiques à des sujets ayant besoin d'un tel traitement.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29090909P | 2009-12-30 | 2009-12-30 | |
US61/290,909 | 2009-12-30 | ||
US36212410P | 2010-07-07 | 2010-07-07 | |
US61/362,124 | 2010-07-07 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2011082267A2 WO2011082267A2 (fr) | 2011-07-07 |
WO2011082267A8 true WO2011082267A8 (fr) | 2011-08-18 |
WO2011082267A3 WO2011082267A3 (fr) | 2011-11-24 |
Family
ID=44188279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/062429 WO2011082267A2 (fr) | 2009-12-30 | 2010-12-29 | Composés triazolo-pyrazine substitués |
Country Status (3)
Country | Link |
---|---|
US (1) | US8329705B2 (fr) |
TW (1) | TW201136932A (fr) |
WO (1) | WO2011082267A2 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9533984B2 (en) | 2013-04-19 | 2017-01-03 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
US9533954B2 (en) | 2010-12-22 | 2017-01-03 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9115163B2 (en) | 2007-10-19 | 2015-08-25 | The Trustees Of Columbia University In The City Of New York | DNA sequence with non-fluorescent nucleotide reversible terminators and cleavable label modified nucleotide terminators |
ME03300B (fr) | 2012-06-13 | 2019-07-20 | Incyte Holdings Corp | Composés tricycliques substitués servant d'inhibiteurs des fgfr |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
WO2016134294A1 (fr) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
EA038045B1 (ru) | 2015-02-20 | 2021-06-28 | Инсайт Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
EA202092649A1 (ru) | 2018-05-04 | 2021-06-21 | Инсайт Корпорейшн | Соли ингибитора fgfr |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US20220281873A1 (en) * | 2019-07-08 | 2022-09-08 | Medshine Discovery Inc. | Compound as porcupine inhibitor and use thereof |
IL291901A (en) | 2019-10-14 | 2022-06-01 | Incyte Corp | Bicyclyl heterocycles as fgr suppressors |
KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
WO2021113479A1 (fr) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr |
CN112979659B (zh) * | 2021-02-22 | 2022-07-08 | 中国医科大学 | 一类HIF-2α小分子抑制剂的制备及用途 |
AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
WO2023072263A1 (fr) * | 2021-10-29 | 2023-05-04 | 南京明德新药研发有限公司 | Composé de pyridine-2(1h)-cétone 5-substituée et son utilisation |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
DE3364438D1 (en) | 1982-10-18 | 1986-08-14 | Pfizer | Triazoloquinoxalines as antidepressants and antifatigue agents |
GB8913011D0 (en) * | 1989-06-06 | 1989-07-26 | Wellcome Found | Anticonvulsant pyrazines |
DK0778277T3 (da) | 1995-12-08 | 2003-10-27 | Pfizer | Substituerede heterocycliske derivater som CRF antagonister |
EP1012151B1 (fr) | 1997-09-02 | 2002-08-07 | Bristol-Myers Squibb Pharma Company | Pyridines a cycle fusionne et a substitution heterocyclyle, antagonistes du facteur de liberation de la cortitropine (crf), utiles dans le traitement des troubles lies au snc et au stress |
IL139197A0 (en) | 1999-10-29 | 2001-11-25 | Pfizer Prod Inc | Use of corticotropin releasing factor antagonists and related compositions |
CA2398956A1 (fr) | 2000-02-14 | 2001-08-16 | Japan Tobacco Inc. | Composition pharmaceutique pour la prophylaxie ou le traitement du stress post-operatoire |
EP1149583A3 (fr) | 2000-04-13 | 2001-11-14 | Pfizer Products Inc. | Combinaison des antagonistes de la facteur de la liberation de la corticotropin et des secrétagogues de l hormone de croissance |
JP2007501272A (ja) | 2003-05-05 | 2007-01-25 | ニューロジェン・コーポレーション | 置換イミダゾロピラジンおよびトリアゾロピラジン誘導体類:gabaaレセプタリガンド類 |
US20060183746A1 (en) * | 2003-06-04 | 2006-08-17 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
US20080194574A1 (en) * | 2003-12-16 | 2008-08-14 | Axxima Pharmaceuticals Ag | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases |
BRPI0809567A2 (pt) | 2007-04-10 | 2014-09-23 | Lundbeck & Co As H | Composto, composição farmacêutica, método para modular a atividade de um receptor de p2x7, para tratar uma condição responsiva à modulação do receptor de p2x7 em um paciente, para inibir a morte de células do gânglio retinal em um paciente, e para determinar a presença ou ausência do receptor de p2x7 em uma amostra, preparação farmacêutica acondiciaonada, e, uso de um composto |
PT2690101E (pt) * | 2007-12-19 | 2015-10-08 | Genentech Inc | 5-anilinoimidazopiridinas e métodos de utilização |
WO2009152133A1 (fr) | 2008-06-10 | 2009-12-17 | Abbott Laboratories | Nouveaux composés tricycliques |
-
2010
- 2010-12-29 US US12/981,105 patent/US8329705B2/en active Active
- 2010-12-29 WO PCT/US2010/062429 patent/WO2011082267A2/fr active Application Filing
- 2010-12-30 TW TW099146871A patent/TW201136932A/zh unknown
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9533954B2 (en) | 2010-12-22 | 2017-01-03 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9533984B2 (en) | 2013-04-19 | 2017-01-03 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
Also Published As
Publication number | Publication date |
---|---|
WO2011082267A2 (fr) | 2011-07-07 |
US20110160215A1 (en) | 2011-06-30 |
WO2011082267A3 (fr) | 2011-11-24 |
US8329705B2 (en) | 2012-12-11 |
TW201136932A (en) | 2011-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011082273A3 (fr) | Composés de pyrroloaminopyrimidine substitués | |
WO2011082270A3 (fr) | Composés imidazopyridinyl-aminopyridine substitués | |
WO2011082267A8 (fr) | Composés triazolo-pyrazine substitués | |
WO2011082266A3 (fr) | Composés hétérocycliques substitués | |
WO2012177844A3 (fr) | Composés d'imidazopyridinyle-aminopyridine substitués | |
WO2010078421A8 (fr) | Composés de 5,6-dihydro-6-phénylbenzo[f]isoquinoléine-2-amines substituées | |
WO2011123678A3 (fr) | Composés de benzo-pyrido-triazolo-diazépine substitués | |
WO2012118812A3 (fr) | Composés hétéroaryles bicycliques substitués condensés en 6,5 | |
WO2011082268A3 (fr) | Composés naphthalényl-pyrimidine substitués | |
WO2011060049A3 (fr) | Antagonistes, de type spiro-oxindole, de l'oncoprotéine mdm2 | |
WO2012075492A3 (fr) | Purine substituée par un carbocycle et composés de 7-déazapurine | |
WO2014062733A3 (fr) | Composés de benzène substitué | |
WO2012065022A3 (fr) | Spiro-oxindoles antagonistes de mdm2 | |
WO2013163190A8 (fr) | Inhibiteurs d'adn pk | |
WO2010111406A3 (fr) | Composés et leurs utilisations thérapeutiques | |
MX2012010434A (es) | Compuestos y composiciones novedosas para atacar a las celulas madre del cancer. | |
WO2012024530A3 (fr) | Conjugués peptide thérapeutique-polymère, particules, compositions et procédés apparentés | |
WO2013061004A8 (fr) | Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines | |
WO2009002808A3 (fr) | Composés de quinazolinone et leurs méthodes d'utilisation | |
WO2011129936A3 (fr) | Compositions et procédés pour la prévention et le traitement du cancer | |
WO2012103810A1 (fr) | Certaines entités chimiques, compositions et procédés | |
WO2013040227A3 (fr) | Composés thérapeutiques | |
WO2015059463A3 (fr) | Bêta-caténine | |
WO2012061342A3 (fr) | Composés de benzo-imidazo-pyrido-diazépine substitués | |
EP2528440A4 (fr) | Norindénoisoquinoléines substituées, leurs synthèses et leurs procédés d'utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10841699 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10841699 Country of ref document: EP Kind code of ref document: A2 |